Home › Liver Cancer (Hepatocellular Carcinoma) › California › Orange
Liver Cancer (Hepatocellular Carcinoma) clinical trials in Orange, CA
14 studies for Liver Cancer (Hepatocellular Carcinoma) are looking for participants at sites in and around Orange (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
RecruitingPhase 1/2
- Research Facility, Orange
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
RecruitingPhase 1/2
- UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
RecruitingPhase 2
- UC Irvine Health. Chao Family Comprehensive Cancer Center, Orange
Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial
RecruitingPhase 1/2
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
Recruiting
- Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
RecruitingPhase 1/2
- Children's Hospital of Orange County, Orange
Patient-Derived Xenografts to Reduce Cancer Health Disparities
RecruitingObservational study
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
RecruitingPhase 3
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RecruitingPhase 1
- UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
RecruitingPhase 1/2
- Children's Hospital Orange County, Orange
Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma
RecruitingPhase 2
- Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
RecruitingPhase 1/2
- University of California Irvine Medical Center, Orange
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RecruitingPhase 2
- University of California, Irvine, Orange
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Orange
Liver Cancer (Hepatocellular Carcinoma) trials in other cities
- Houston, TX31 studies
- New York City, NY24 studies
- Dallas, TX19 studies
- Los Angeles, CA19 studies
- Boston, MA18 studies
- Cleveland, OH18 studies
- Philadelphia, PA16 studies
- Chicago, IL16 studies
- Pittsburgh, PA15 studies
- San Francisco, CA14 studies
- Jacksonville, FL14 studies
- San Antonio, TX13 studies
Other studies in Orange
- Non-Small Cell Lung Cancer25 studies
- Metastatic Cancer20 studies
- Colorectal Cancer16 studies
- Ovarian Cancer16 studies
- Pancreatic Cancer15 studies
- Melanoma14 studies
- Breast Cancer14 studies
- Lung Cancer14 studies
- Prostate Cancer14 studies
- Stomach Cancer13 studies
- Cancer (all types)13 studies
- Acute Myeloid Leukemia13 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.